Neuraceq (florbetaben F-18) has received regulatory approval in China, a first for an Alzheimer’s disease imaging tracer, according to its developers.
Life Molecular Imaging said that Chinese partner Sinotau Pharmaceutical Group will manufacture the imaging agent at sites in Jiangsu, Guangdong, and Sichuan provinces, to ensure product distribution to the majority of the Chinese market.
With new disease-modifying drugs for Alzheimer’s disease “on the horizon in China,” early and reliable diagnosis of patients using PET radiotracers specific to amyloid plaque is critical for successful patient management, Life Molecular said.
Neuraceq was approved in the U.S. and in Europe in 2014.
